ライフサイエンスコーパス: aggressiveness

1 P1 dimer is an important contributor to TNBC aggressiveness.

2 ll marker and seems to correlate with tumour aggressiveness.

3 at itself was associated with prostate tumor aggressiveness.

4 istent T cell exposure to antigen and T cell aggressiveness.

5 degree of inflammation correlates with tumor aggressiveness.

6 expression, high levels of PLD1/2, and high aggressiveness.

7 o amoeboid transition contributing to tumour aggressiveness.

8 in tumor cell migration, a measure of tumor aggressiveness.

9 s in the stroma may promote increased cancer aggressiveness.

10 echanism underlying tumour heterogeneity and aggressiveness.

11 s (miRNAs) involved in tumor development and aggressiveness.

12 ion and have been linked to tumor growth and aggressiveness.

13 btype of breast cancer characterized by high aggressiveness.

14 glycine metabolism and is linked to clinical aggressiveness.

15 d this often correlates with increased tumor aggressiveness.

16 ranial and skeletal development, and reduced aggressiveness.

17 G PET/CT, and to evaluate classic factors of aggressiveness.

18 ironmental stress and to increase growth and aggressiveness.

19 ock protein (HSP)H1/105 in function of their aggressiveness.

20 ature of solid tumors associated with cancer aggressiveness.

21 performed to test alternative definitions of aggressiveness.

22 adenocarcinoma (PDAC) is a marker of disease aggressiveness.

23 cal and pathologic features, including tumor aggressiveness.

24 th worsening prognosis and increased disease aggressiveness.

25 defined as angiocrine factors, provoke tumor aggressiveness.

26 with caveolin-1 to enhance pancreatic cancer aggressiveness.

27 helpful in the assessment of prostate cancer aggressiveness.

28 desmoplasia is thought to confer biological aggressiveness.

29 ameters for evaluating neoplastic growth and aggressiveness.

30 e metabolic changes that promote cancer cell aggressiveness.

31 s, two characteristics associated with tumor aggressiveness.

32 correlated with an increase in breast cancer aggressiveness.

33 geneous group of tumors with a wide range of aggressiveness.

34 by repressing the basal phenotype, and thus aggressiveness.

35 relate with pancreatic ductal adenocarcinoma aggressiveness.

36 endothelial cells (TECs) regulate tumor cell aggressiveness.

37 lymphoma metabolism as a marker of clinical aggressiveness.

38 nocarcinoma (PDAC) cells and increases their aggressiveness.

39 basis of the MRS data with respect to cancer aggressiveness.

40 n is also associated with tumour hypoxia and aggressiveness.

41 tinguish between breast cancers of different aggressiveness.

42 uggesting that it may be implicated in tumor aggressiveness.

43 an alternative to ErbB2 mechanism to promote aggressiveness.

44 d MEMO1 expression is associated with cancer aggressiveness.

45 s a major regulator of tumor development and aggressiveness.

46 ns among centers with intermediate levels of aggressiveness.

47 etion correlates with disease penetrance and aggressiveness.

48 y in mutated tumors and increases with tumor aggressiveness.

49 g to increased degree of disorder and cancer aggressiveness.

50 astases as well as other indicators of tumor aggressiveness.

51 ease glutamate is a key watershed in disease aggressiveness.

52 ly interfering with pancreatic cancer cells' aggressiveness.

53 rcinomas, in a manner correlating with tumor aggressiveness.

54 sification and provide new insights on tumor aggressiveness.

55 echanism contributing to race-related tumour aggressiveness.

56 te cancer cell lines with varying degrees of aggressiveness.

57 ent conditions is well correlated with their aggressiveness.

58 ss to create computed micrographs reflecting aggressiveness.

59 -independent role of ABHD5 in modulating PCa aggressiveness.

60 which NF-kappaB pathways promote biological aggressiveness.

61 the levels of which contributes to invasive aggressiveness.

62 linics, to characterize quantitatively tumor aggressiveness.

63 mportant roles in multiple aspects of cancer aggressiveness.

64 llular state associated with increased tumor aggressiveness.

65 d identification of prognostic indicators of aggressiveness.

66 erized by subordinate status and the lack of aggressiveness.

67 f therapeutic agents; it also promotes tumor aggressiveness.

68 ables discrimination between prostate cancer aggressiveness.

69 ase-control or case-case analyses of disease aggressiveness.

70 umor suppressor gene that could affect tumor aggressiveness; a reduced level of SMPD3 is an independe

71 umor characteristics, (ii) a marker of tumor aggressiveness and (iii) to look at the impact of adjuva

72 ion (EMT) has been associated with increased aggressiveness and acquisition of migratory properties p

73 models characterized by different degrees of aggressiveness and angiogenesis, we show that the combin

74 el branching correlated very well with tumor aggressiveness and angiogenesis.

75 cells a set of genes associated with cancer aggressiveness and bone metastases, and the most upregul

76 Evi1/EVI1 and Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing compar

77 ss may have profound implications for tumour aggressiveness and clinical outcome.

78 ion in early breast cancer can predict tumor aggressiveness and clinical outcomes in large patient po

79 d UTP18 expression correlates with increased aggressiveness and decreased survival in numerous cancer

80 creased H3K9me3 may mediate DDLPS-associated aggressiveness and dedifferentiation properties.

81 Here we demonstrate that tradeoffs between aggressiveness and defensiveness (i.e., targeting advers

82 cule BUB1B may offer a predictive marker for aggressiveness and effective drug response.

83 rine FGF4-FGFR1/Jag1-Notch2 loop inhibits LC aggressiveness and enhances chemosensitivity.

84 revealed that these mice manifest increased aggressiveness and higher pentylenetetrazole (PTZ)-induc

85 d the role of IL4 in promoting breast cancer aggressiveness and how its targeting may improve the eff

86 ection for autoreactivity leads to increased aggressiveness and if this selection plays out equally i

87 -30% of breast tumors and is associated with aggressiveness and increased risk of recurrence and deat

88 rying a mesenchymal signature, which defines aggressiveness and invasion, and are associated with com

89 Invasiveness underlies cancer aggressiveness and is a hallmark of malignancy.

90 Due to intrinsic aggressiveness and lack of effective therapies, prognosi

91 so have utility beyond an indicator of tumor aggressiveness and lends itself as a promising therapeut

92 cer (BCa) treatment is based on the presumed aggressiveness and likelihood of cancer recurrence.

93 olarity regulator in LSCC that affects tumor aggressiveness and metastasis.

94 ion in primary tumor tissues can predict PCa aggressiveness and metastasis.

95 been regarded as a central factor for tumor aggressiveness and metastasis.

96 The acquisition of aggressiveness and metastatic features in breast tumours

97 progression by modulating the ovarian tumor aggressiveness and microenvironment.

98 Osteopontin expression correlates with tumor aggressiveness and poor clinical outcome in patients.

99 r promoting activities correlate with tumour aggressiveness and poor clinical prognosis.

100 vels of miR-194 were associated with disease aggressiveness and poor outcome.

101 ar phenotype correlates with increased tumor aggressiveness and poor patient survival.

102 therapy and correlates with chemoresistance, aggressiveness and poor prognosis in NSCLC patients.

103 (CDCP1), which has been correlated with the aggressiveness and poor prognosis of multiple carcinomas

104 s to identify genetic loci that govern tumor aggressiveness and poor survival.

105 reased expression is associated with disease aggressiveness and poor survival.

106 increasingly used clinically to gauge tumor aggressiveness and potentially guide care.

107 creatic cancer as a potential index of tumor aggressiveness and predictor of survival.

108 R1 expression positively correlates with the aggressiveness and progression of prostate tumors.

109 e newly identified Notch3-Pin1 axis in T-ALL aggressiveness and progression.

110 plays an important role for prostate cancer aggressiveness and progression.

111 g in mouse and human LCs diminished lymphoma aggressiveness and prolonged mouse survival.

112 to play a crucial role by increasing cancer aggressiveness and promoting resistance to therapy.

113 ked defects of this pathway to breast cancer aggressiveness and proposed Wnt/PCP signalling as a ther

114 etic age is an important determinant of TNBC aggressiveness and provide rationale for investigating a

115 hough tumor hypoxia is associated with tumor aggressiveness and resistance to cancer treatment, many

116 NANOG, SOX2, and OCT4, associated with tumor aggressiveness and resistance to conventional anticancer

117 s stable and associated with increased tumor aggressiveness and resistance to VEGF blockade in serial

118 These differences could affect disease aggressiveness and response to therapy.

119 GICs are essential to tumor aggressiveness and retain the capacity for self-renewal

120 Despite its aggressiveness and short latency, current progress on it

121 tient samples and correlated with markers of aggressiveness and shorter survival.

122 Males differed consistently in activity, aggressiveness and social plasticity.

123 moral inflammatory cells is related to tumor aggressiveness and suggests that the response to treatme

124 g in various organs and with a large span of aggressiveness and survival rates.

125 in a dramatic augmentation in tumor size and aggressiveness and that NAF-1 overexpression enhances th

126 ubtype have a poor prognosis due to inherent aggressiveness and the lack of targeted therapeutics.

127 HCC carries a dismal prognosis owing to its aggressiveness and the undruggable nature of its main ge

128 A splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African Ame

129 role for BIRC3 expression as a predictor of aggressiveness and therapeutic resistance to TMZ and RT

130 cular subtypes exhibit differential clinical aggressiveness and therapeutic response, which may have

131 ressing ovarian CSCs as a mechanism of tumor aggressiveness and therapy resistance in human SOC.

132 ment and have been linked to increased tumor aggressiveness and treatment resistance.

133 NF8 is an appealing strategy to tackle tumor aggressiveness and treatment resistance.

134 key cellular process associated with greater aggressiveness and tumorigenicity in vivo.

135 lcoholism, borderline personality disorders, aggressiveness and violence in crime, obsessive-compulsi

136 ssion of PKC, a kinase associated with tumor aggressiveness and widely implicated in malignant transf

137 vo noninvasive assessment of prostate cancer aggressiveness, and both modalities have comparable perf

138 s behavioral traits, including sexual drive, aggressiveness, and fear conditioning.

139 in the RTK/ERK pathway with prostate cancer aggressiveness, and highlighted the potential importance

140 S100A9 as important mediators of tumor cell aggressiveness, and highlights the therapeutic potential

141 al abnormalities such as cognitive deficits, aggressiveness, and hyperactivity.

142 Parameters of contrast enhancement, risk of aggressiveness, and nodule with fibrous septum were eval

143 festations of JMML in terms of age of onset, aggressiveness, and organ infiltration with monocytes/ma

144 ociated with HCC disease progression, cancer aggressiveness, and poorer prognosis of HCC patients.

145 ein involved in homeostatic pathways, cancer aggressiveness, and stem cell state maintenance.

146 to determine the extent of the disease, its aggressiveness, and the need for any treatment.

147 s to stem cell-like dedifferentiation, tumor aggressiveness, and therapy resistance in cancer have su

148 ssed cyclooxygenase-2, an indicator of tumor aggressiveness, and they were able to adjust their gluta

149 lls results in reduced cell survival, cancer aggressiveness, and tumor growth through altering the ba

150 ged as important modulators of breast cancer aggressiveness, and we have investigated the ability of

151 ose expression correlates with breast cancer aggressiveness are divided by micrographs of biomarkers

152 K, and ATF6 are crucial for tumor growth and aggressiveness as well as for microenvironment remodelin

153 for a role for EC JAM-C in tumor growth and aggressiveness as well as recruitment of pericytes to ne

154 ervention is associated with decreased tumor aggressiveness, as well as increased senescence and auto

155 y breathiness, which presumably softened the aggressiveness associated with a large body size.

156 lome assessments revealed that breast cancer aggressiveness associated with Cav1 CGI shore methylatio

157 e repair at premalignant stages or to reduce aggressiveness at the tumor stage.

158 These studies reveal a GATA2-IGF2 aggressiveness axis in lethal prostate cancer and identi

159 rget genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo.

160 pes are associated with measures of clinical aggressiveness, but do not perfectly predict patient out

161 (MTA1) in human cancer contributes to tumor aggressiveness, but the role of endogenous MTA1 in cance

162 nscripts that correlate with different tumor aggressiveness, but their specific functions and biologi

163 automatic classification of prostate cancer aggressiveness by combining apparent diffusion coefficie

164 3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and en

165 Tk neuron activation overcame reduced aggressiveness caused by eliminating a variety of sensor

166 involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.

167 Significant correlation was found between aggressiveness classes and maximum Cho+Cr/Cit ratio (rho

168 Furthermore, we develop an aggressiveness classifier consisting of 25 DNA methylati

169 , and identification of molecular markers of aggressiveness could provide valuable biochemical insigh

170 to chemotherapy but also participates in its aggressiveness due to the consequent high degree of hypo

171 Control variables included sex, age, trait aggressiveness, exposure to violent media, interest in g

172 ntly associated with common markers of tumor aggressiveness (high serum alpha-fetoprotein levels, P =

173 supported by ANXA6+ EVs is predictive of PDA aggressiveness, highlighting a therapeutic target and po

174 malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not c

175 We determined an miR signature defining aggressiveness in B-cell non-Hodgkin lymphomas (NHL) and

176 Ectopic expression of TLK2 leads to enhanced aggressiveness in breast cancer cells, which may involve

177 expression levels are correlated with tumor aggressiveness in carcinoma and aggressive sarcoma; howe

178 ting the existence of distinct mechanisms of aggressiveness in different immunogenetic subsets of CLL

179 Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate t

180 ARs) represents an established biomarker for aggressiveness in most common malignant diseases, includ

181 aggressive (due to DGEs) strongly decreased aggressiveness in opponents (due to IGEs).

182 ata show that S1P signalling promotes tumour aggressiveness in OSCC and identify S1P signalling as a

183 in the expression of TUBB3 gene, a marker of aggressiveness in ovarian cancer (OC), encoding betaIII-

184 sensitive to modulation of serotonin than is aggressiveness in the shore crab.

185 d androgen concentrations may explain female aggressiveness in this species and give dominant breeder

186 5 gene, is overexpressed and associated with aggressiveness in various endocrine-related tumors, but

187 TNBC pathobiology, and its knockdown reduced aggressiveness in vitro, and tumorigenesis and metastasi

188 cogenic transformation of NSCs and instates 'aggressiveness' in human glioblastoma stem cells.

189 CRPC-like cells increases proliferation and aggressiveness, in vitro and in vivo.

190 correlated with LPA receptor and markers of aggressiveness including Ki67 and pAKT.

191 n the characteristics associated with tumour aggressiveness, including invasion, migration, and oxyge

192 hat accompanied the progression to increased aggressiveness induced by in vivo passage of mouse EOC c

193 hlight a novel mechanism underlying clinical aggressiveness involving a mutated ribosomal protein, po

194 rom numerous cancers suggests that increased aggressiveness is accompanied by up-regulation of signal

195 This aggressiveness is in part attributed to the closely inte

196 refore, identification of new biomarkers for aggressiveness is needed.

197 hybrid E/M phenotype in characterizing tumor aggressiveness is tissue and subtype specific.

198 Lower aggressiveness, lower risks of infanticide from female k

199 Not unlike its reported function as a tumor aggressiveness marker, CD151 in humans thus marks and en

200 Moreover, their aggressiveness matched patient observations, and their r

201 Cancer aggressiveness may result from the selective pressure of

202 and hypoxia can be a prognostic indicator of aggressiveness, metastasis, and poor response to therapy

203 as chemotherapy, may increase the metabolic aggressiveness of a tumor due to drug-mediated selection

204 ural basis of the perceived dangerousness or aggressiveness of animals, which we refer to more genera

205 , the mechanism through which FOXC1 controls aggressiveness of basal-like breast cancer remains to be

206 in the development, metastasis and level of aggressiveness of breast cancer, raising the possibility

207 ve been shown to play a critical role in the aggressiveness of breast cancer.

208 nd TWIST1 are positively correlated with the aggressiveness of breast carcinomas.

209 At least part of the ethnic disparity in the aggressiveness of breast tumors might be transmitted thr

210 rogen resistance 1 gene) are associated with aggressiveness of breast tumors.

211 anism by which ERalpha signaling reduces the aggressiveness of cancer cells, and demonstrate that C/E

212 effective characterization of the state and aggressiveness of cancerous tumors.

213 within this ES signature responsible for the aggressiveness of cancers can lead to a potential cure.

214 e raised the intriguing possibility that the aggressiveness of carcinomas derives not from their exis

215 e, patients with AD specifying limits in the aggressiveness of care less frequently received mechanic

216 ergrowth in obesity is linked with increased aggressiveness of certain cancers.

217 at activates Notch signaling, sustaining the aggressiveness of certain mouse and human B cell lymphom

218 these signatures may be used to predict the aggressiveness of DCIS, and discuss future perspectives

219 tion to identify a clinical indicator of the aggressiveness of DCIS.

220 senchymal (EMT) transition, correlating with aggressiveness of disease.

221 gnosed pancreatic cancer correlated with the aggressiveness of disease.

222 Thus, the higher aggressiveness of Drosophila males reflects the sexually

223 Nicotine also promoted aggressiveness of established tumors as well as the epit

224 t prognostic factor in the evaluation of the aggressiveness of gastric cancer, in addition to clinica

225 The aggressiveness of glioblastoma multiforme (GBM) is defin

226 transfer of specific miRNA that enhance the aggressiveness of glioblastoma.

227 rogenase activity can profoundly enhance the aggressiveness of human breast cancer cells, while thera

228 multifocal propensity of PC and categorized aggressiveness of individual PC foci based on DNA methyl

229 The aggressiveness of invasive ductal carcinoma (IDC) of the

230 cificity, combined with both the general low aggressiveness of invasive P. longicornis towards other

231 tentially acts as a driving mechanism in the aggressiveness of Keap1-deficient lung ADs.

232 transcriptional modulator that increases the aggressiveness of malignant glial neoplasms.

233 ion of patients which can guide the type and aggressiveness of management.

234 The aggressiveness of melanoma is due to its capacity to pro

235 models, we demonstrate decreased growth and aggressiveness of miR-200-overexpressing UCS cell lines.

236 ution of the Epstein-Barr virus (EBV) to the aggressiveness of nasopharyngeal carcinoma (NPC).

237 in the contribution of EBV infection to the aggressiveness of NPC are discussed in this review.

238 xperiments showed that TGF-beta enhanced the aggressiveness of ovarian cancer cells by upregulating V

239 and a distinguishing feature underlying the aggressiveness of ovarian cancer cells.

240 Multiple pathways contribute to the aggressiveness of ovarian cancer, including hypoxic sign

241 irst correlated KLF8 overexpression with the aggressiveness of ovarian patient tumors and then tested

242 experiments showed that caveolin-1-enhanced aggressiveness of pancreatic cancer cells is dependent o

243 r stem cell (CSC) has been demonstrated with aggressiveness of pancreatic cancer.

244 e that germ line genetic mutations alter the aggressiveness of paragangliomas, treatment decisions ar

245 orrelative studies showed that ASPM promotes aggressiveness of PDAC by maintaining Wnt-beta-catenin s

246 ration of PtenCKO control mice increased the aggressiveness of prostate tumors relative to noncastrat

247 phylogeny, virulence genes, host range, and aggressiveness of Pseudomonas syringae strains closely r

248 tic duet was indicated to be involved in the aggressiveness of PTC, but its prognostic value in PTC-r

249 mice formed papillomas, indicating that the aggressiveness of RDEB-cSCC is mutation-independent.

250 nge from 1.7 to 230 Gg CO2e depending on the aggressiveness of residential density.

251 n whose expression level correlates with the aggressiveness of several tumors.

252 al tension and matricellular fibrosis in the aggressiveness of SMAD4 mutant pancreatic tumors and hig

253 correlated with the age of onset of cancer, aggressiveness of the disease and survival.

254 als induced by external antigen increase the aggressiveness of the disease.

255 xpression were inversely correlated with the aggressiveness of the disease.

256 in expression positively correlates with the aggressiveness of the tumor.

257 rs) recurrence, which reflects the intrinsic aggressiveness of the tumor.

258 may contribute in part to the differences in aggressiveness of the two glioma types.

259 This contributes to the intrinsic aggressiveness of these cells by upregulating Rab27-depe

260 mma-secretase inhibitor, suggesting that the aggressiveness of those tumors can be attributed, at lea

261 e metastasis models confirmed the remarkable aggressiveness of TRPV6-overexpressing tumors.

262 In vivo, Sig1R expression enhanced the aggressiveness of tumor cells by potentiating invasion a

263 mating opportunities, or others individuals' aggressiveness or fighting ability.

264 This effect is not moderated by sex, prior aggressiveness, or parental monitoring and is only sligh

265 vity analyses, however, illustrated that the aggressiveness-outcome association was dependent on the

266 Additionally, risk of aggressiveness parameter was demonstrated to be associat

267 Cancer aggressiveness promotes the clustering of drug nanocarri

268 elationship between SLFN5 expression and RCC aggressiveness raises the possibility of developing uniq

269 ay better reflect tumor biologic behavior or aggressiveness rather than tumor burden in metastatic NS

270 (black and white, elevated plus maze tests), aggressiveness (resident-intruder test), and locomotor a

271 son score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 x 10

272 al rating system (metabolic imaging lymphoma aggressiveness scale, or MILAS) was used to assess prima

273 o the center-level, assigning each center an aggressiveness score based on relative utilization of hi

274 oral modifications with ideation slowing and aggressiveness, sometimes contrasting with mild severity

275 re had a strong association with features of aggressiveness such as high grade, hormone receptor nega

276 ify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in

277 lmark of tumor development, progression, and aggressiveness, the pHLIP technology may prove useful in

278 idermal melanocytes, and it is known for its aggressiveness, therapeutic resistance, and predispositi

279 hypoxia has been proposed to increase tumor aggressiveness, these data suggest WNT11 as a possible t

280 d an earlier age of onset (around 30 years), aggressiveness (three had nodal infiltration requiring t

281 hypothesized that IH could potentiate cancer aggressiveness through activation of the cyclooxygenase-

282 cell abilities, which in turn influences PDA aggressiveness through crosstalk that is mediated by ext

283 ERT in stress hormone-induced ovarian cancer aggressiveness through inducing Slug, providing novel bi

284 mechanism by which RCP promotes cancer cell aggressiveness through sequential beta1 integrin stabili

285 whose expression negatively correlates with aggressiveness to create computed micrographs reflecting

286 r each of 8 racial/ethnic groups, biological aggressiveness (triple-negative cancers, lymph node meta

287 Well-differentiated, potentially low-aggressiveness tumors form the heterogeneous molecular c

288 cluding EGFR family proteins to promote TNBC aggressiveness using in vitro and in vivo studies.

289 Increased PDA aggressiveness was dependent on tumor cell-mediated upta

290 riation on the assessment of prostate cancer aggressiveness was examined in a second retrospective co

291 identify molecular pathways involved in ARMS aggressiveness, we first characterized the migratory beh

292 ofiles from patient cohorts displaying tumor aggressiveness, we identify and experimentally validate

293 Predictive markers of cancer aggressiveness were identified, including various free f

294 OPN, Spp-1) is widely associated with cancer aggressiveness when produced by tumor cells, but its imp

295 rve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.

296 Moreover, these cells exhibit increased aggressiveness with enhanced migration and invasive pote

297 seeking, poor planning skills and heightened aggressiveness with poor self-regulation.

298 found to be associated with prostate cancer aggressiveness with the exact or similar pattern in the

299 s molecular-based support for determining PC aggressiveness with the potential to impact clinical dec

300 with thyroid cancer--can help determine the aggressiveness with which the diagnostic studies of thyr